Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824848 | 0.99 | USP2 (0.33) | USP2SMN1; SMN2EPHX2MAPK1EPHX1 | |
| SCHEMBL27858888 | 0.99 | USP2 (0.33) | USP2SMN1; SMN2EPHX2MAPK1EPHX1 | |
| SCHEMBL28975611 | 0.86 | USP2 (0.34) | USP2SMN1; SMN2EPHX2MAPK1CTSK | |
| SCHEMBL5478401 | 0.84 | USP2 (0.35) | USP2SMN1; SMN2EPHX2MAPK1CTSK | |
| SCHEMBL28670928 | 0.84 | USP2 (0.35) | USP2SMN1; SMN2EPHX2MAPK1CTSK | |
| SCHEMBL16636874 | 0.84 | USP2 (0.35) | USP2SMN1; SMN2EPHX2MAPK1CTSK | |
| SCHEMBL31078891 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2EPHX2EPHX1CTSK | |
| SCHEMBL11954522 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2EPHX2EPHX1CTSK | |
| SCHEMBL11954515 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2EPHX2EPHX1CTSK | |
| SCHEMBL324691 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2EPHX2MAPK1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | USP2 2235/4885SMN1; SMN2 1967/4885EPHX2 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.